The Mark Egly Foundation aims to significantly improve the lives of individuals with and without Alpha1 Antitrypsin Deficiency.
We desire to fund projects that involve the additional production of Alpha1 Antitrypsin, as a greater demand for AAT will be needed, as more patients are found with AATD and more uses for AAT become apparent to the medical community.
We have a need to fund researchers who understand the need to confirm how Alpha1 Antitrypsin can treat conditions previously unknown as comorbidities to the circulating Alpha1 Antitrypsin levels in the body! These conditions can be found within the patent claims for new uses of Alpha1 Antitrypsin.